Childhood ADHD medication may reduce psychosis risk

Commonly prescribed medication for attention deficit hyperactivity disorder (ADHD) could lower the risk of developing serious psychotic disorders later in life, new research suggests.

Three containers lie open on a table with pills spilling out of them

Experts found that children treated with methylphenidate before the age of 13 were less likely to go on to develop conditions such as schizophrenia in adulthood.

The findings challenge long-standing concerns that stimulant medications may increase the risk of psychosis, experts say.

Reassuring findings

ADHD is a common neurodevelopmental condition that affects attention, behaviour and impulse control, and is often diagnosed in childhood. While most young people do not develop severe mental illness, a small proportion go on to experience psychotic disorders in later life.

To better understand whether medication plays a role in this risk, researchers from the University of Edinburgh and University College Dublin analysed health data from nearly 700,000 people born in Finland, including around 4,000 individuals diagnosed with ADHD.

The team found no evidence that treatment with methylphenidate increased the likelihood of developing psychosis. Instead, children who received the medication at a younger age showed a reduced risk compared with those who were not treated early.

Early treatment

Methylphenidate is the most commonly prescribed medication for ADHD and is widely used to manage symptoms such as inattention and hyperactivity.

Researchers say the findings suggest the drug may have benefits beyond symptom control, potentially influencing longer-term brain development in ways that reduce vulnerability to severe mental illness.

However, the apparent protective effect was only seen in those treated during childhood. The same benefit was not observed in individuals who began treatment during adolescence or adulthood.

Further research

The study comes at a time when ADHD diagnoses are rising rapidly worldwide, particularly among adults, prompting increased debate about the long-term safety of stimulant medications.

Researchers say the findings highlight the importance of early diagnosis and age-appropriate treatment, as well as the need for further research into how these medications affect the brain at different stages of development. 

The study was funded by the St John of God Research Foundation.

We know that when children with ADHD are followed into adulthood, a small but significant minority develop psychotic disorders such as schizophrenia. A critical question has been whether ADHD medication causes that risk, or whether this is a case where correlation does not equal causation. Our findings suggest the medication itself is not driving that risk.

Overall, these findings are reassuring. The fact that early treatment was associated with a lower long-term risk of psychosis suggests these medications may do more than manage symptoms in childhood – they may also have longer-term protective effects, though this requires further research.

There are important developmental differences between the childhood brain and the teenage or adult brain. We can’t assume that the effects of stimulant medication will be the same across different stages of life. Given the rapid rise in adult ADHD treatment, understanding these differences is now an urgent priority.

Tags

2026
Future of Health and Care
Research